ClinicalTrials.gg
CompletedNCT01360021BAIUpdated Mar 11, 2014Results posted

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

A Phase 3 interventional study of Symbicort and Symbicort in Asthma, sponsored by AstraZeneca. Completed at 41 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2014-03-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
44th of 108
214 · median 124
Started
2011
with 1 other
Phase 3
51 of 110
3 open now
Registered
72nd of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 44th largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2011, is one of 51 in phase 3, and was the 72nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 12 years and above
  • Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months
  • Pre-bronchodilator ≥ 45% and ≤ 85% of predicted normal
  • Patients with reversible airway obstruction
  • Documented daily use of inhaled for ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2
  • Hospitalized during previous 6 months for asthma
  • Required emergency treatment more than once during previous 6 months for an asthma-related condition
  • Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment
  • Respiratory infection affecting the asthma within 30 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
214 participants (actual)

Study arms

  • Active comparator
    1 Symbicort/inhaler

    Symbicort BA MDI 2x160/4.5 μg twice daily

    Drug: Symbicort

  • Active comparator
    Symbicort/inhaler

    Symbicort AC pDMI 2x160/4.5 μg twice daily

    Drug: Symbicort

  • Active comparator
    Budesonide/inhaler

    Budesonide AC pMDI 2x160 μg twice daily

    Drug: Budesonide

Interventions

  • DrugSymbicort

    Breath actuated metered dose inhaler

  • DrugSymbicort

    Actuation counter pressured metered dose inhaler

  • Actuation counter pressured metered dose inhaler

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1) - Post Dose

    Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.

    Time frame: 60 minutes post-dose in clinic visits at baseline, and week 0, 3, 7, 12 and Trt Avg

  2. Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose

    Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.

    Time frame: Pre AM dose in clinic visits at baseline, and week 3, 7, 12 and Trt Avg

Secondary outcomes

  1. Peak Expiratory Flow

    Time frame: Recorded morning upon rising and evening before sleep for 14 weeks

  2. Asthma Symptoms Score (Total)

    The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.

    Time frame: Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks

  3. Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)

    The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.

    Time frame: Recorded 6:00 - 11:00 AM for 14 weeks

  4. Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)

    Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.

    Time frame: Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks

07

Results

Posted Mar 11, 2014
Limitations and caveats
No. of participants in the safety analysis set is (71 for all the group) as 1 patients from the Budesonide group has not taken any dose of the IP, so not included in the Safety population.

Participant flow

Participant flow — Overall Study
MilestoneSymbicort BA MDISymbicort pMDIBudesonide
Started717172
Completed636765
Not completed847
Withdrew: Eligibility criteria + other211
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject402
Withdrew: Adverse event233

Outcome measures

PrimaryForced Expiratory Volume in 1 Second (FEV1) - Post Dose

Descriptive statistics for post-dose FEV1 (L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.

Time frame:
60 minutes post-dose in clinic visits at baseline, and week 0, 3, 7, 12 and Trt Avg
Reported as:
Geometric mean · Liter
Forced Expiratory Volume in 1 Second (FEV1) - Post Dose
LiterSymbicort BA MDISymbicort pMDIBudesonide
Baseline2.09 ± 31.461.97 ± 27.162.12 ± 26.34
Week 02.49 ± 32.142.35 ± 25.972.28 ± 27.18
Week 32.52 ± 31.982.34 ± 26.312.30 ± 30.22
Week 72.59 ± 32.172.35 ± 27.222.33 ± 29.29
Week 122.52 ± 30.712.39 ± 27.312.30 ± 28.27
Treatment Average2.53 ± 30.572.37 ± 26.332.30 ± 28.36
Statistical analysis
  • Symbicort pMDI vs Budesonide · ANCOVA · p = 0.001 · Estimated geometic mean ratio: 1.10 · 95% CI 1.06 to 1.14Symbicort AC pMDI 2x160/4.5 µg bid vs Budesonide AC pMDI 2x160 µg bid
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · Estimated geometric mean ratio: 1.01 · 95% CI 0.97 to 1.05The comparisons was used to assess therapeutic equivalence of Symbicort AC pMDI and Symbicort BA MDI. Assay sensitivity was demonstrated before proceeding to assess therapeutic equivalence of the 2 Symbicort products.
PrimaryForced Expiratory Volume in 1 Second (FEV1) - Pre Dose

Descriptive statistics for predose FEV1(L) by visit; Baseline defined as the last pre-dose value prior to 1st dose of randomized therapy. Trt Avg = Mean of all available valid values after randomization.

Time frame:
Pre AM dose in clinic visits at baseline, and week 3, 7, 12 and Trt Avg
Reported as:
Geometric mean · Liters
Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose
LitersSymbicort BA MDISymbicort pMDIBudesonide
Baseline2.09 ± 31.461.97 ± 27.162.12 ± 26.34
Week 32.32 ± 32.792.12 ± 28.292.22 ± 31.21
Week 72.40 ± 32.862.11 ± 29.962.25 ± 29.01
Week 122.34 ± 30.842.17 ± 31.292.23 ± 30.15
Average of treatment period2.34 ± 30.152.15 ± 29.152.23 ± 29.36
Statistical analysis
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · Estimated geometric mean ratio: 1.03 · 95% CI 0.99 to 1.08The comparisons was used to assess therapeutic equivalence of Symbicort AC pMDI and Symbicort BA MDI. Assay sensitivity was demonstrated before proceeding to assess therapeutic equivalence of the 2 Symbicort products.
SecondaryPeak Expiratory Flow
Time frame:
Recorded morning upon rising and evening before sleep for 14 weeks
Reported as:
Mean · L/Min
Peak Expiratory Flow
L/MinSymbicort BA MDISymbicort pMDIBudesonide
Morning Peak expiratory flow (Baseline)357.95 ± 100.59335.70 ± 102.99360.46 ± 103.09
Evening Peak expiratory flow (Baseline)364.61 ± 103.62347.86 ± 110.80367.64 ± 102.73
Evening Peak expiratory flow (Treatment Average)379.96 ± 104.72362.99 ± 112.63348.94 ± 97.94
Morning Peak expiratory flow (Treatment Average)376.28 ± 106.76353.69 ± 108.72343.59 ± 98.12
Statistical analysis
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · p = 0.825 · Mean difference (net): 1.49 · 95% CI -11.81 to 14.80Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported.
  • Symbicort pMDI vs Budesonide · ANCOVA · p = 0.001 · Mean difference (net): 33.52 · 95% CI 20.11 to 46.93Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported.
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · p = 0.810 · Mean difference (net): 1.48 · 95% CI -10.66 to 13.61Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported.
  • Symbicort pMDI vs Budesonide · ANCOVA · p = 0.001 · Mean difference (net): 32.25 · 95% CI 20.01 to 44.49Secondary efficacy variables were analyzed as continuous data, comparing mean changes from baseline to the average of the double-blind treatment period between treatments. No adjustment were made for multiplicity and nominal p-values were reported.
SecondaryAsthma Symptoms Score (Total)

The total score is calculated as sum of the morning and evening scores of each day and the treatment period mean score is defined as the mean of all total score recorded during the 12-week treatment period. Trt Avg=Mean total score of double-blind period values.(day/night score ranges from 0 to 3; 0=no asthma symptoms; 3= unable to do normal activities (or to sleep) due to asthma). Higher score represents worse outcome.

Time frame:
Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks
Reported as:
Mean · Asthma score on a scale of 0 to 3
Asthma Symptoms Score (Total)
Asthma score on a scale of 0 to 3Symbicort BA MDISymbicort pMDIBudesonide
Baseline2.04 ± 0.981.92 ± 0.722.12 ± 0.88
Treatment Average (Trt Avg)1.68 ± 1.101.45 ± 0.912.02 ± 0.96
Statistical analysis
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · p = 0.272 · Mean difference (net): 0.13 · 95% CI -0.10 to 0.35ANCOVA model includes treatment and country as a factor and baseline value as covariate.
SecondaryNight-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)

The percentage of days with no awakenings due to asthma. Baseline= Mean % awakening-free nights during run-in period ; Trt Avg=Mean % awakening-free nights during double-blind period.

Time frame:
Recorded 6:00 - 11:00 AM for 14 weeks
Reported as:
Mean · Percentage of days with no awakenings
Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)
Percentage of days with no awakeningsSymbicort BA MDISymbicort pMDIBudesonide
Baseline78.54 ± 28.9778.76 ± 29.7681.59 ± 25.32
Treatment Average (Trt Avg)83.73 ± 30.9089.93 ± 21.4084.62 ± 26.31
Statistical analysis
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · p = 0.025 · Mean difference (net): -6.10 · 95% CI -11.41 to -0.79ANCOVA model includes treatment and country as a factor and baseline value as covariate.
SecondaryUse of Rescue Medication Day and Night (Total Daily Rescue Medication Use)

Total daily rescue medication use is calculated as the sum of morning and evening use each day and averaged over the 12 weeks treatment periods to calculate the treatment period mean. Baseline= Mean rescue medication used during run-in period ; Trt Avg=Mean rescue medication used during double-blind period.

Time frame:
Recorded between 6:00 - 11:00 AM from previous 12 hours and 6:00 -11:00 PM from previous 12 hours for 14 weeks
Reported as:
Mean · Inhalations/24 hrs
Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)
Inhalations/24 hrsSymbicort BA MDISymbicort pMDIBudesonide
Baseline2.55 ± 2.482.19 ± 1.752.65 ± 2.36
Treatment Average (Trt Avg)1.81 ± 2.671.26 ± 1.602.34 ± 2.38
Statistical analysis
  • Symbicort BA MDI vs Symbicort pMDI · ANCOVA · p = 0.258 · Mean difference (net): 0.26 · 95% CI -0.19 to 0.71ANCOVA model includes treatment and country as a factor and baseline value as covariate.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide—0/71 (0%)3/71 (4.2%)
Symbicort BA MDI—0/71 (0%)2/71 (2.8%)
Symbicort pMDI—1/71 (1.4%)7/71 (9.9%)
Most frequent serious events
Most frequent serious events
EventBudesonideSymbicort BA MDISymbicort pMDI
APPENDICITISInfections and infestations0/710/711/71
Most frequent other events
Most frequent other events
EventBudesonideSymbicort BA MDISymbicort pMDI
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/712/717/71

Baseline characteristics

All Randomized patients

Age, Continuous
Age, Continuous(Years)Symbicort BA MDISymbicort pMDIBudesonideTotal
Mean42.83 ± 16.15642.62 ± 16.87342.72 ± 14.42442.72 ± 15.770
Age, Customized
Age, Customized(Participants)Symbicort BA MDISymbicort pMDIBudesonideTotal
12 - <18 years68721
18 - <65 years605662178
65 - <75 years44210
>= 75 years1315
Sex: Female, Male
Sex: Female, Male(Participants)Symbicort BA MDISymbicort pMDIBudesonideTotal
Female374735119
Male34243795
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Symbicort BA MDISymbicort pMDIBudesonideTotal
American Indian or Alaska Native0000
Asian4116
Native Hawaiian or Other Pacific Islander0011
Black or African American971127
White576357177
More than one race0000
Unknown or Not Reported1023
Years since asthma diagnosis
Years since asthma diagnosis(Years)Symbicort BA MDISymbicort pMDIBudesonideTotal
Mean24.26 ± 14.89124.12 ± 15.12824.38 ± 15.18324.25 ± 14.998
% Predicted FEV1 (Visit 2)
% Predicted FEV1 (Visit 2)(%)Symbicort BA MDISymbicort pMDIBudesonideTotal
Mean67.27 ± 10.04865.02 ± 11.13568.49 ± 9.92466.93 ± 10.434
% Reversibility in FEV1 (Visit 2)
% Reversibility in FEV1 (Visit 2)(%)Symbicort BA MDISymbicort pMDIBudesonideTotal
Mean23.93 ± 15.72828.04 ± 14.71223.64 ± 12.69225.20 ± 14.491
% Reversibility in FEV1 (Visit 3)
% Reversibility in FEV1 (Visit 3)(%)Symbicort BA MDISymbicort pMDIBudesonideTotal
Mean26.43 ± 16.66228.22 ± 16.11824.88 ± 14.23526.51 ± 15.692

1 further baseline measures are reported on the registry.

08

Study locations

41 sites
  • Research Site
    Huntington Beach, California, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Rancho Mirage, California, United States
  • Research Site
    Riverside, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    San Jose, California, United States
  • Research Site
    Tallahassee, Florida, United States
  • Research Site
    Savannah, Georgia, United States
  • Research Site
    River Forest, Illinois, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Metairie, Louisiana, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Wheaton, Maryland, United States
  • Research Site
    North Dartmouth, Massachusetts, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Rolla, Missouri, United States
  • Research Site
    Skillman, New Jersey, United States
  • Research Site
    North Syracuse, New York, United States
  • Research Site
    Rochester, New York, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Collegeville, Pennsylvania, United States
  • Research Site
    Lincoln, Rhode Island, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Spartanburg, South Carolina, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Tacoma, Washington, United States
  • Research Site
    Greenfield, Wisconsin, United States
  • Research Site
    Madison, Wisconsin, United States
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Sevlievo, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Balassagyarmat, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Salgotarjan, Hungary
  • Research Site
    Szazhalombatta, Hungary
  • Research Site
    Ekaterinburg, Russia, Russian Federation
  • Research Site
    Moscow, Russia, Russian Federation
09

References and documents

Publications

  • Murphy KR, Dhand R, Trudo F, Uryniak T, Aggarwal A, Eckerwall G. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI. Respir Med. 2015 Feb;109(2):170-9. doi: 10.1016/j.rmed.2014.12.009. Epub 2015 Jan 3. PubMed 25596138 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2011
First posted
May 25, 2011
Start
Nov 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Mar 11, 2014
Last update
Mar 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01360021
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 25, 2011
Start date
Nov 2011
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Mar 11, 2014
Last update
Mar 11, 2014

Study contacts

Goran Eckerwall, MD
study director · AstraZeneca R&D, Mölndal
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion